Background There is a growing armamentarium for the treatment of moderate-to-severe
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …

… Author links open overlay panel Pablo A. Olivera 1 ∗ , Juan S. Lasa 1 2 ∗ , Stefanos …
Pablo Andres Olivera, MD (Formal analysis: Supporting; Investigation: Lead; Methodology: …

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

… Pablo A. Olivera, critically reviewed the content of the paper, discussed the statements and
contributed to the final manuscript. Peter Bossuyt, critically reviewed the content of the paper, …

Background In the context of an ageing inflammatory bowel disease (IBD) population,
cardiovascular comorbidities become particularly relevant. Novel small molecule drugs (SMDs) for …

Several efforts have been made to improve the available therapeutic armamentarium of
patients with immune-mediated inflammatory disorders (IMIDs) leading to the development of …

As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective
alternatives within healthcare systems. Addressing various challenges in the clinical …

Introduction Sphingosine-1-phosphate modulators are approved for the treatment of multiple
sclerosis and are under development for other immune-mediated conditions; however, …

To the Editor: α4β7 is a prototypic gut integrin that regulates homing of memory and effector
T cells to the gut. 1 Vedolizumab is an anti-α4β7 monoclonal antibody and is approved by …

Latin America (LATAM) is a large region comprising 47 countries and territories. Each one
carries a different cultural and historical background, diverse political systems, and a …